Although the CCL2-CCR2 axis-based treatment of cardiovascular disease may not immediately impact cardiovascular disease therapeutic practice, it does open the door for clinical translation of chemokines and their receptor modulators. This evidence concerns the gene CCR2 and cardiovascular disorder.